Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia (APHERESE)

March 24, 2026 updated by: Assistance Publique - Hôpitaux de Paris

New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) :

  • Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP
  • Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP
  • Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP
  • Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP
  • Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

Study Type

Observational

Enrollment (Actual)

236

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris, France, 75014
        • Hopital Cochin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

pregnancy with preeclampsia and without preeclampsia

Description

Inclusion Criteria:

  • Age from 18 to 50 years old
  • Singleton pregnancies between 20 and 41 weeks of gestation
  • Preeclampsia
  • Normal pregnancy

Exclusion Criteria:

  • Age<18
  • Infectious disease: HIV, HBV or HCV
  • Multiple pregnancies
  • Opposition of the patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
control
pregnancy without preeclampsia
Biological: A collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
preeclampsia
pregnancy with preeclampsia
Biological: A collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ratio sFlt-1/PlGF
Time Frame: Day 0
measurement of of sFlT-1 and PlGF
Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinetics of these ratios sFlt-1/PlGF during pregnancy
Time Frame: until 5 month
measurement of of sFlT-1 and PlGF at many times
until 5 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

URC-CIC Paris Descartes Necker Cochin
INSERM UMR-S 1139

Investigators

  • Study Director: Edouard Lecarpentier, MD, PhD, Centre Hospitalier Intercommunal de Créteil

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2017

Primary Completion (Actual)

June 12, 2019

Study Completion (Actual)

June 12, 2019

Study Registration Dates

First Submitted

April 13, 2017

First Submitted That Met QC Criteria

June 13, 2017

First Posted (Actual)

June 16, 2017

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SC3455

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preeclampsia

Clinical Trials on A collection of maternal plasma and serum

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe